BIOLASE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 21, 2024 at 04:05 pm
Share
BIOLASE, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 13.49 million compared to USD 14.05 million a year ago. Net loss was USD 5.33 million compared to USD 9.86 million a year ago. Basic loss per share from continuing operations was USD 1.76 compared to USD 128.06 a year ago.
For the full year, sales was USD 49.16 million compared to USD 48.46 million a year ago. Net loss was USD 20.63 million compared to USD 28.63 million a year ago. Basic loss per share from continuing operations was USD 29.44 compared to USD 418.13 a year ago.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.
BIOLASE, INC. 
